BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

4:10 PM
 | 
Aug 01, 2019
 |  BC Innovations  |  Emerging Company Profile

NeoPhore: Driving neoantigen production via DNA mismatch repair

NeoPhore is making tumor cells more visible to the immune system by triggering neoantigen production

NeoPhore is turning cold tumors hot by inhibiting DNA mismatch repair to produce more of the neoantigens that trigger immune attack.

Immuno-oncology companies are developing therapies based on neoantigens -- tumor-specific peptides that the immune system regards as non-self -- including T cell therapies and cancer vaccines that either target or deliver the newly formed antigens.

NeoPhore Ltd. wants to take a different tack by creating the neoantigens in the patient to make the tumors more visible to the immune system. The company is developing small molecules to inhibit DNA mismatch repair (MMR) and create a pool of neoantigens to turn “dark” tumors “light” that can be treated with immunotherapies.

“Evidence suggests MMR inhibition will re-program a wholly new, diverse collection of neoantigens and related immune signaling inside patient cancers,” CEO Jeff Roix told BioCentury.

NeoPhore spun out of U.K. cancer company PhoreMost Ltd. in 2017, in collaboration with co-founders Alberto Bardelli and Giovanni Germano at University of Turin, to focus on...

Read the full 788 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Innovations

Article Purchase

$100 USD
More Info >